====== Anticoagulant Related Intracerebral Hemorrhage Diagnosis ====== [[Computerized tomography]] (CT) remains the initial [[neuroimaging]] tool of choice for acute [[Intracranial Hemorrhage Diagnosis]] ((Heit JJ, Iv M, Wintermark M. Imaging of [[Intracranial Hemorrhage]]. J Stroke. 2017 Jan;19(1):11-27. doi: 10.5853/jos.2016.00563. Epub 2016 Dec 12. PMID: 28030895; PMCID: PMC5307932.)). The presence of a [[blood-fluid level]] has been suggested as a marker for [[Anticoagulant Related Intracerebral Hemorrhage]] ((Pfleger MJ, Hardee EP, Contant CF Jr, Hayman LA. [[Sensitivity]] and [[specificity]] of fluid-blood levels for [[coagulopathy]] in acute [[intracerebral hematoma]]s. AJNR Am J Neuroradiol. 1994 Feb;15(2):217-23. PMID: 8192064.)) ((Gökçe E, Beyhan M, Acu B. Evaluation of Oral Anticoagulant-Associated Intracranial Parenchymal Hematomas Using CT Findings. Clin Neuroradiol. 2015 Jun;25(2):151-9. doi: 10.1007/s00062-014-0292-8. Epub 2014 Jan 29. PMID: 24474263.)), but with the exception of one study (a sub-study of [[INTERACT 2]]), most published studies are [[case report]]s or were done on small [[sample]]s ((Pfleger MJ, Hardee EP, Contant CF Jr, Hayman LA. [[Sensitivity]] and [[specificity]] of fluid-blood levels for [[coagulopathy]] in acute [[intracerebral hematoma]]s. AJNR Am J Neuroradiol. 1994 Feb;15(2):217-23. PMID: 8192064.)) ((Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, Moy CS, Silbergleit R, Steiner T, Suarez JI, Toyoda K, Wang Y, Yamamoto H, Yoon BW; ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive Blood-Pressure Lowering in Patients with Acute [[Cerebral Hemorrhage]]. N Engl J Med. 2016 Sep 15;375(11):1033-43. doi: 10.1056/NEJMoa1603460. Epub 2016 Jun 8. PMID: 27276234; PMCID: PMC5345109.)) In a study of 2065 patients from the [[INTERACT]]-2 study, blood-fluid levels on baseline CT (found in 19 patients in the sample) were associated with the use of [[warfarin]] as well as poor outcome 90 days after ICH ((Sato S, Delcourt C, Zhang S, Arima H, Heeley E, Zheng D, Al-Shahi Salman R, Stapf C, Tzourio C, Robinson T, Lindley RI, Chalmers J, Anderson CS; INTERACT2 Investigators. Determinants and Prognostic Significance of Hematoma Sedimentation Levels in Acute Intracerebral Hemorrhage. Cerebrovasc Dis. 2016;41(1-2):80-6. doi: 10.1159/000442532. Epub 2015 Dec 16. PMID: 26671408.)). ---- In 855 patients with CT-confirmed acute ICH scanned within 48 h of symptom onset, Almarzouki et al. investigated the [[sensitivity]] and [[specificity]] of the presence of a CT-defined blood-fluid level (rated blinded to anticoagulant status) for identifying concomitant anticoagulant use. They also investigated the association of the presence of a blood-fluid level with six-month case fatality. Eighteen patients (2.1%) had a blood-fluid level identified on CT; of those with a blood-fluid level, 15 (83.3%) were taking anticoagulants. The specificity of the blood-fluid level for OAC-ICH was 99.4%; the sensitivity was 4.2%. They could not detect an association between the presence of a blood-fluid level and an increased risk of death at six months (OR = 1.21, 95% CI 0.28-3.88, p = 0.769). The presence of a blood-fluid level should alert clinicians to the possibility of OAC-ICH, but the absence of a blood-fluid level is not useful in excluding OAC-ICH ((Almarzouki A, Wilson D, Ambler G, Shakeshaft C, Cohen H, Yousry T, Al-Shahi Salman R, Lip GYH, Houlden H, Brown MM, Muir KW, Jäger HR, Werring DJ. Sensitivity and specificity of blood-fluid levels for oral anticoagulant-associated intracerebral hemorrhage. Sci Rep. 2020 Sep 23;10(1):15529. doi: 10.1038/s41598-020-72504-7. Erratum in: Sci Rep. 2021 Apr 28;11(1):9485. PMID: 32968133; PMCID: PMC7511300.)). ===== References =====